Literature DB >> 30520388

miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth.

Evita Maria Lindholm1, Suvi-Katri Leivonen2, Eldri Undlien1, Daniel Nebdal1, Anna Git3, Carlos Caldas3, Anne-Lise Børresen-Dale1, Kristine Kleivi1,4.   

Abstract

BACKGROUND: HER2 positive Breast Cancers (BC) have aggressive behavior and poor prognosis. Previously, we have identified miR-342-5p as an upstream regulator of HER2 signaling, as well as inhibitor of HER2 positive BC cell line growth.
OBJECTIVE: Here, we aimed to further investigate the molecular mechanisms behind miR-342-5pinduced HER2 pathway deregulation.
METHOD: Two HER2 amplified breast cancer cell lines were transiently transfected with miR-342-5p mimic or negative control, and gene expression was analyzed by Agilent microarrays. Three clinical datasets with BC patients were used to identify correlations between candidate genes and miR-342- 5p, and associations with survival.
RESULTS: Pathway analyses of all deregulated genes revealed a significant suppression of the HER2 downstream pathways ERK/MAPK and SAPK/JNK, whereas the miR-342-5p predicted target genes were enriched for pathways associated with cell motility.Biological functions linked to mitochondrial stability were ranked among the top toxicological functions in both gene lists. Among the most deregulated genes, Cytochrome B5 Reductase 3 (CYB5R3) and Rap Guanine Nucleotide Exchange Factor 6 (RAPGEF6) significantly anticorrelated and correlated, respectively, with miR-342-5p in all three clinical BC datasets. Low CYB5R3 levels and high RAPGEF6 levels were significantly associated with survival, although this was not directly associated with HER2 expression.
CONCLUSION: Our data suggest that miR-342-5p overexpression in HER2 positive BC cell lines elicits broad effects on HER2 downstream signaling, cell motility and mitochondrial stability. Together these effects may render cells less proliferative and more sensitive to cellular stress. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  CYB5R3; HER2 signaling; MAPK; RAPGEF6; miR-342-5p; non-coding.

Mesh:

Substances:

Year:  2019        PMID: 30520388     DOI: 10.2174/2211536608666181206124922

Source DB:  PubMed          Journal:  Microrna


  14 in total

1.  miR-342-5p inhibits osteosarcoma cell growth, migration, invasion, and sensitivity to Doxorubicin through targeting Wnt7b.

Authors:  Qing Liu; Zhenting Wang; Xiaohua Zhou; Mingying Tang; Wei Tan; Tianshi Sun; Youwen Deng
Journal:  Cell Cycle       Date:  2019-10-10       Impact factor: 4.534

Review 2.  Circulating non-coding RNAs as a diagnostic and management biomarker for breast cancer: current insights.

Authors:  Hamed Hosseinalizadeh; Mehrdad Mahmoodpour; Ammar Ebrahimi
Journal:  Mol Biol Rep       Date:  2021-10-22       Impact factor: 2.316

3.  Identification of an 8-miRNA signature as a potential prognostic biomarker for glioma.

Authors:  Baowei Ji; Lihua Chen; Qiang Cai; Qiao Guo; Zhibiao Chen; Du He
Journal:  PeerJ       Date:  2020-09-28       Impact factor: 2.984

4.  Aberrant expression of a five-microRNA signature in breast carcinoma as a promising biomarker for diagnosis.

Authors:  Amirreza Bitaraf; Sadegh Babashah; Masoud Garshasbi
Journal:  J Clin Lab Anal       Date:  2019-10-08       Impact factor: 2.352

5.  Identification of novel dysregulated circular RNAs in early-stage breast cancer.

Authors:  Arunagiri Kuha Deva Magendhra Rao; Vittal Rangan Arvinden; Deepa Ramasamy; Krishna Patel; Balaiah Meenakumari; Priya Ramanathan; Shirley Sundersingh; Velusami Sridevi; Thangarajan Rajkumar; Zdenko Herceg; Harsha Gowda; Samson Mani
Journal:  J Cell Mol Med       Date:  2021-02-05       Impact factor: 5.310

6.  Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance.

Authors:  Yi-Ying Wu; Hsing-Fan Lai; Tzu-Chuan Huang; Yu-Guang Chen; Ren-Hua Ye; Ping-Ying Chang; Shiue-Wei Lai; Yeu-Chin Chen; Cho-Hao Lee; Wei-Nung Liu; Ming-Shen Dai; Jia-Hong Chen; Ching-Liang Ho; Yi-Lin Chiu
Journal:  Cell Death Dis       Date:  2021-10-05       Impact factor: 8.469

7.  Long non-coding RNA LINC00346 contributes to cisplatin resistance in nasopharyngeal carcinoma by repressing miR-342-5p.

Authors:  Zheqing Cui; Tian Pu; Yujie Zhang; Jia Wang; Yulin Zhao
Journal:  Open Biol       Date:  2020-05-13       Impact factor: 6.411

8.  CBNA: A control theory based method for identifying coding and non-coding cancer drivers.

Authors:  Vu V H Pham; Lin Liu; Cameron P Bracken; Gregory J Goodall; Qi Long; Jiuyong Li; Thuc D Le
Journal:  PLoS Comput Biol       Date:  2019-12-02       Impact factor: 4.475

9.  Identification of the miRNA-mRNA regulatory pathways and a miR-21-5p based nomogram model in clear cell renal cell carcinoma.

Authors:  Yiqiao Zhao; Zijia Tao; Xiaonan Chen
Journal:  PeerJ       Date:  2020-11-04       Impact factor: 2.984

10.  Long Noncoding RNA OIP5-AS1 Promotes the Disease Progression in Nasopharyngeal Carcinoma by Targeting miR-203.

Authors:  Jian Tang; Chengxiao Fu; Yanwen Li; Shuangqin Chen; Xiaoxin Jiang; Wenqian Xu; Haitao Xie
Journal:  Biomed Res Int       Date:  2021-02-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.